Evidence map›Paper›PMID 39342023›Full record

ArticleDrug delivery and translational research2024

Formulation of protein-loaded nanoparticles via freeze-drying.

Matilde Durán-Lobato, Sulay Tovar, Tadeu de Oliveira Diz, Miguel Chenlo, Clara V Álvarez, María José Alonso

Abstract read
PubMed Publisher
In one paragraph

Article in Drug delivery and translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Matilde Durán-LobatoCenter for Research in Molecular Medicine & Chronic Diseases (CIMUS), University of Santiago de Compostela, Campus Vida, Santiago de Compostela, 15782, Spain. mduran@us.es.
Sulay TovarCenter for Research in Molecular Medicine & Chronic Diseases (CIMUS), University of Santiago de Compostela, Campus Vida, Santiago de Compostela, 15782, Spain.
Tadeu de Oliveira DizCenter for Research in Molecular Medicine & Chronic Diseases (CIMUS), University of Santiago de Compostela, Campus Vida, Santiago de Compostela, 15782, Spain.
Miguel ChenloNeoplasia & Endocrine Differentiation P0L5, Centre for Research in Molecular Medicine and Chronic Disease (CIMUS), Av Barcelona s/n, Santiago de Compostela, 15782, Spain.
Clara V ÁlvarezNeoplasia & Endocrine Differentiation P0L5, Centre for Research in Molecular Medicine and Chronic Disease (CIMUS), Av Barcelona s/n, Santiago de Compostela, 15782, Spain.
María José AlonsoCenter for Research in Molecular Medicine & Chronic Diseases (CIMUS), University of Santiago de Compostela, Campus Vida, Santiago de Compostela, 15782, Spain. mariaj.alonso@usc.es.ORCID 0000-0001-7187-9567

Funding

FP7 Ideas: European Research Council 281035
6 · The paper itself

Abstract

Several nanotechnology-based formulation strategies have been reported for the oral administration of biological drugs. However, a prerequisite often overlooked in developing these formulations is their adaptation to a solid dosage form. This study aimed to incorporate a freeze-drying step, using either mannitol or sucrose laurate (SLAE), into the formulation of new insulin-zinc nanocomplexes to render them resistant to intestinal fluids while maintaining a high protein loading. The resulting freeze-dried insulin-zinc nanocomplexes exhibited physicochemical properties consistent with the target product profile, including a particle size of ∼ 100 nm, a zeta potential close to neutrality (∼ -15 mV) and a high association efficiency (> 90%). Importantly, integrating the freeze-drying step in the formulation significantly improved the colloidal stability of the system and preserved the stability of the insulin molecules. Results from in vitro and in vivo studies indicated that the insulin activity remained fully retained throughout the entire formulation and freeze-drying processes. In brief, we present a novel protein formulation strategy that incorporates a critical freeze-drying step, resulting in a dry powder enabling efficient protein complexation with zinc and optimized for oral administration.

Indexed as

Freeze DryingInsulinNanoparticlesSucroseAdministration, OralAnimalsDrug CompoundingDrug StabilityHumansMaleMannitolParticle SizeZincInsulinMannitolSucroseZincFreeze-dryingIntestinal absorptionNanocomplexesNanostructuresOral administrationPeptide/protein delivery

Identifiers

PMID39342023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.